ITM will be holding the Satellite Symposium “Towards Optimizing the Application of Radiotheranostics in the Management of NET Patients” during the ENETS Conference in Barcelona on March 07, 2019.
Although Radiotheranostics has been used to manage patients with neuroendocrine tumors (NET) for many years, it is only recently that Targeted Radionuclide Therapy (TRT) has been approved for the treatment of patients with NET. At the present time, the radiopharmaceutical c.a. 177Lu-DOTATATE is positioned as second line or later in the treatment algorithm of patients with gastroenteropancreatic (GEP) NET.
A second TRT with n.c.a. 177Lu-DOTATOC is currently under investigation in the phase III clinical trial COMPETE in pancreatic and clinically non-functioning NET, using Everolimus as a comparator. This study has the option to include patients as first line therapy.
The optimal positioning in the treatment algorithm has yet to be determined. In addition, the approach to subgroups of patients with large bone and tumor burdens needs to be defined.
In this Radiotheranostics Symposium these critical aspects, together with a comparison between the two TRT options and the need for an optimized personalized dosimetry will be discussed.
It is hoped that the symposium will facilitate an understanding of the novel opportunities that Radiotheranostics has to offer in the treatment of patients with GEP NET, together with an appreciation of the opportunities that lie ahead in its further development.
Chair: Professor Martyn Caplin
Royal Free London & University College London
Professor Martyn Caplin, Royal Free London & University College London
The Positioning of Targeted Radionuclide Therapy in the Treatment Algorithm of Patients with Neuroendocrine Tumors
Philippe Ruszniewski, University of Paris VII, Beaujon Hospital (15 mins)
N.c.a 177Lu-DOTATOC and c.a. 177Lu-DOTATATE - Similarities and Differences, Dosimetry
Dr Guillaume Nicolas, Universitätsspital Basel (15 mins)
Management of Patients with Large Volume Liver Metastases and Large Volume Bone Metastases
Dr Simona Glasberg, Hadassah-Hebrew University Medical Center (15 mins)
Panel Discussion and Summary
If you have any queries, please do not hesitate to contact us at enets(at)itm.ag